Investor Presentaiton slide image

Investor Presentaiton

Investor presentation ADA 2019 Slide 34 R&D milestones in 2019 Project TresibaⓇ RyzodegⓇ OzempicⓇ Anti-IL-21 Q1 2019 US submission (CV label update) Q2 2019 Phase 3b results (vs glargine U300) CN regulatory decision ✓ FOCUS trial initiation (OT²) FORTE initiation (dose trial) Phase 2 results Clinical milestones¹ Regulatory milestones¹ Q3 2019 Q4 2019 FLOW trial initiation (Outcomes trial³) LAI287 LAIsema Oral semaglutide Amylin - AM833 Tri-agonist 1706 PYY 1562 Semaglutide combination Phase 1 initiation US submission US submission (CV) ✓ Phase 2 initiation EsperoctⓇ/N8-GP Concizumab Somapacitan Diabetes Phase 2 results Phase 1 results SOUL trial initiation (CVOT) EU submission US regulatory decision Japan submission PoC phase 2 initiation US regulatory decision CHMP recommendation✓ Obesity NASH Phase 3 initiation (GHD) Haemophilia Growth disorders Phase 1 results Phase 1 results Japan regulatory decision Phase 3 initiation US and EU submission (AGHD) Japan submission (AGHD) 1 Expected to be published in the given quarter or in the subsequent quarterly company announcement; 2 Diabetic retinopathy outcome trial; 3 Diabetes kidney disease outcome trial; GG-co-agonist in obesity phase 1 decisive results are now expected in 2020; OT: Outcomes trial; GHD: Growth hormone deficiency; AGHD: Adult growth hormone deficiency; CVOT: Cardiovascular outcomes trial; CV: Cardiovascular; PoC: proof of concept; NASH: nonalcoholic steatohepatitis
View entire presentation